logo
Golden Years Home Care Continues to Transform Lives with Exceptional Dementia Home Care in San Diego County

Golden Years Home Care Continues to Transform Lives with Exceptional Dementia Home Care in San Diego County

A happy caregiver with a happy elderly person
Golden Years Home Care reaffirms its commitment to dementia home care in San Diego County. Founder Ken Ballard's team provides personalized in‑home support that eases families' burden and enriches clients' lives. Trained caregivers manage medication, daily tasks, confusion, agitation, and wandering, while engaging clients with music, light exercise, and memory activities. Families gain peace of mind, flexible schedules, and respite as loved ones stay safe, dignified, and connected at home.
San Diego, CA - Ken Ballard, founder of Golden Years Home Care, proudly announces the organization's ongoing commitment to providing compassionate and specialized dementia home care in San Diego County. For years, Golden Years Home Care has been a trusted name in delivering high-quality home care in San Diego County, ensuring families receive the support they need while offering peace of mind through personalized care solutions.
Caring for a loved one with dementia can be emotionally and physically challenging. Golden Years Home Care eases this burden by offering tailored in-home care services designed to enhance the quality of life for both patients and their families. Their trained caregivers provide companionship, medication management, and daily living assistance—all while creating a safe and familiar environment that helps slow cognitive decline. Studies show that patients with dementia thrive best in their own homes, and Golden Years Home Care makes this possible with expert, compassionate support.
One of the key benefits of dementia home care in San Diego County is the one-on-one attention that ensures individualized care plans. Unlike facility-based care, home care allows for flexible scheduling, personalized routines, and specialized activities that stimulate memory and cognitive function. Golden Years Home Care's caregivers are extensively trained in dementia care techniques, ensuring they can manage symptoms like confusion, agitation, and wandering with patience and expertise.
Beyond medical and daily living support, Golden Years Home Care emphasizes emotional and social well-being. Their caregivers engage clients in meaningful activities, from music therapy to light exercises, fostering a sense of purpose and joy. Families also benefit from respite care, giving them time to recharge while knowing their loved one is in capable hands. With home care in San Diego County from Golden Years, families no longer have to navigate dementia care alone.
Golden Years Home Care remains dedicated to raising the standard of dementia care in San Diego County. Ken Ballard states, 'Our mission is to provide dignity, comfort, and expert care to those living with dementia while supporting their families every step of the way.' For more information about their dementia home care in San Diego, please visit their website at https://goldenyearshomecare.com/san-diego-ca
About Golden Years Home Care in San Diego, CA:
Golden Years Home Care is a leading provider of in-home care services in San Diego County, specializing in dementia care, senior assistance, and respite care. With a team of highly trained caregivers, they deliver compassionate, personalized care that allows seniors to age gracefully in the comfort of their own homes.
Media Contact
Company Name: Golden Years Home Care (San Diego, CA)
Contact Person: Ken Ballard
Email: Send Email
Phone: (916) 333-0383
Address:301 SPRUCE ST, STE 101
City: San Diego
State: California 92103-5626
Country: United States
Website: https://goldenyearshomecare.com/san-diego-ca/
Source: Grow Senior Care Marketing
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

17 treated after possible chemical spill in Doral, authorities say
17 treated after possible chemical spill in Doral, authorities say

CBS News

time13 minutes ago

  • CBS News

17 treated after possible chemical spill in Doral, authorities say

A chemical leak at a warehouse near Miami International Mall on Tuesday afternoon sickened 17 people - two of whom were hospitalized - and prompted a large response from Miami-Dade Fire Rescue. Fire officials said about 30 rescue units rushed to the scene on Northwest 19th Street after a call that began as a medical emergency was later upgraded to a hazardous materials incident. Firefighters conducted triage for patients while also working to locate and contain the source of the leak. Seventeen people were treated for mostly respiratory issues, according to Miami-Dade Fire Rescue. Two of those patients were taken to Jackson Memorial Hospital for further care. All of the injuries were described as non-life-threatening. Authorities have not yet identified the chemical that leaked inside the warehouse area. Officials said everyone affected is expected to recover.

Walmart Recalls Shrimp From Indonesia Over Radioactive Contamination Fears
Walmart Recalls Shrimp From Indonesia Over Radioactive Contamination Fears

Bloomberg

time43 minutes ago

  • Bloomberg

Walmart Recalls Shrimp From Indonesia Over Radioactive Contamination Fears

Walmart has recalled frozen, raw shrimp sold in 13 states because federal health officials say it could have potential radioactive contamination. The U.S. Food and Drug Administration asked Walmart to pull three lots of Great Value brand frozen shrimp from stores after federal officials detected Cesium-137, a radioactive isotope, in shipping containers and a sample of breaded shrimp imported from Indonesia.

Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk's breakup with Hims
Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk's breakup with Hims

Yahoo

timean hour ago

  • Yahoo

Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk's breakup with Hims

Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service, are currently soaring after the company announced that it will partner with Novo Nordisk to offer the lowest-ever out-of-pocket prices for Ozempic and Wegovy. Unsold completed new-build inventory is so high this $34B homebuilder is turning to investors 'Job hugging' is the newest career trend: Here's what it means—and why Gen Z is into it Spotify just redesigned the way you'll 'listen' to audiobooks According to a press release posted early on August 18, GoodRx has struck a deal with the pharmaceutical giant Novo Nordisk to sell its popular semaglutide medications, Ozempic and Wegovy, for just $499 per month to 'eligible self-paying customers.' GoodRx doesn't sell or dispense any drugs itself, but rather provides savings and coupons that can be applied in pharmacies. Its exclusive Ozempic and Wegovy offerings, available starting today, are the lowest out-of-pocket costs for the medications available on the market. The news comes just weeks after Novo Nordisk cut ties with the telehealth company Hims & Hers Health (NYSE: HIMS) over claims that Hims & Hers was selling 'knockoff' versions of Wegovy. It's a dispute that reflects a broader discussion around whether compounded semaglutide drugs—or non-FDA approved versions of brand-name medicines—are a violation of intellectual property laws. As of this writing, GoodRx's stock is up by more than 30% since market close. Here's what to know about Novo Nordisk's latest partnership and its ongoing legal battles against compounded GLP-1s. GoodRx's collaboration with Novo Nordisk In the last year alone, GoodRx reports that nearly 17 million people visited the site searching for information and savings on GLP-1 medications—a 22% increase from the previous year. 'Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,' Wendy Barnes, GoodRX president and CEO, said in the press release. 'By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them.' In the past, a spokesperson told Fast Company, GoodRx has worked with both Novo Nordisk and its competitor Eli Lilly to offer commercially insured patients manufacturer savings cards on GLP-1s. The company has also offered savings on other types of weight loss/diabetes treatments, including Contrave, Dexcom G7, Lantus, and Qsymia. However, this is the first time that GoodRx has offered a cash price for a GLP-1. The $499 monthly self-pay cost will be available at more than 70,000 retail locations nationwide. Novo Nordisk's current legal battles over compounded GLP-1s So far, investors' response to GoodRx's new collaboration has been overwhelmingly positive. It stands in sharp contrast to Hims & Hers' recent breakup with Novo Nordisk, which caused the telehealth company's share prices to plummet in late June. Hims & Hers and Novo Nordisk parted ways over Hims & Hers' offering of compounded versions of Wegovy. Back in 2022, the Food and Drug Administration (FDA) declared a shortage of GLP-1 medications including Ozempic and Wegovy. Under this shortage notice, pharmacies were permitted to make compounded versions of the brand-name drugs using their active ingredient, semaglutide, and sell them at a lower cost. However, Hims & Hers has continued to sell its compounded version of Wegovy long after the FDA lifted the shortage back in February. Now, Novo Nordisk is arguing that these compounded drugs are both a violation of its intellectual property and potentially dangerous to patients, due to their lack of FDA approval. Early this month, Novo Nordisk announced 14 new lawsuits against small pharmacies, telehealth providers, and weight-loss clinics over compounded versions of Ozempic and Wegovy—bringing its total cases filed on the matter up to more than 130 in 40 states. Experts say that federal compounding laws are just vague enough to allow for various interpretations, meaning that Novo Nordisk's current legal challenges could shape the way courts interpret those boundaries in the future. In a statement to Yahoo Finance, Barnes offered a clear look into GoodRx's stance on compounded drugs: 'There's no question we could have tried to do something sooner from a compounded alternative pathway, but we have been very clear in our belief that it needed to be FDA-approved, lawfully approved. It just wasn't a pathway that we were going to support,' she said. This post originally appeared at to get the Fast Company newsletter:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store